Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas

 
• By Alaric DeArment

The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.

Gilead's Kite and Arcellx announced an expansion to their CAR-T development partnership. • Source: Shutterstock

More from Deals

More from Business